THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS. - Wikidata - awgldk - TriplyDB

THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.

THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.

http://www.wikidata.org/entity/Q35054462

about

Integrated therapy for HIV and tuberculosis Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011)What is the optimal first line antiretroviral therapy in resource-limited settings?Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Evaluation of adverse drug reactions in HIV positive patients in a tertiary care hospital.Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.Approach to acute kidney injury in HIV-infected patients in South Africa.

P2860

Q26749428-E2FEAE97-6B4C-41CB-A21B-854C61F6601F Q34169277-8CB92F5B-F688-4A83-BEF0-927E8E248FA1 Q34384142-25AE6CD0-A658-4ADD-A641-86FC330A9D80 Q34455442-CE049C27-9C3C-463B-801D-3297AE4741B4 Q35041606-9DBFB342-838B-4A3E-A794-D9DF3CC5AE3A Q42368090-A1FE587B-BDE6-4DB7-9849-4692E81D29E8 Q52641455-DE7003C3-A26C-458A-B616-4922FB2957EC

P2860

THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.

http://www.wikidata.org/entity/Q35054462

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

THE RISKS OF CONCURRENT TREATM ...... H HIV-ASSOCIATED TUBERCULOSIS.

@ast

THE RISKS OF CONCURRENT TREATM ...... H HIV-ASSOCIATED TUBERCULOSIS.

@en

type

label

THE RISKS OF CONCURRENT TREATM ...... H HIV-ASSOCIATED TUBERCULOSIS.

@ast

THE RISKS OF CONCURRENT TREATM ...... H HIV-ASSOCIATED TUBERCULOSIS.

@en

prefLabel

THE RISKS OF CONCURRENT TREATM ...... H HIV-ASSOCIATED TUBERCULOSIS.

@ast

THE RISKS OF CONCURRENT TREATM ...... H HIV-ASSOCIATED TUBERCULOSIS.

@en

P1433

Q35054462-006D8605-7414-43D5-9CDB-727A89560058

P1476

Q35054462-E0227509-A0A4-4685-86C2-A387B65DCD60

P2093

Q35054462-267BDBB9-76D9-44CC-A1F4-309485B61AB4

Q35054462-AD73E7CB-B1A5-49B8-8AB0-836E795A2788

P2860

Q35054462-0B233BE9-FCB2-4896-B727-8F88888B10D4

Q35054462-0F5B6F14-D6DF-40AC-9777-474308B16F23

Q35054462-2B50E5F1-7505-4B90-8B0B-E06A02CB6951

Q35054462-2C61F7AA-48F4-4FE7-80D3-82799C8D84DC

Q35054462-59AC25CF-91C5-4867-9807-B50049E5A171

Q35054462-6CF4E907-6EA9-4C8D-8C1C-B5B4177CF33C

Q35054462-6F34C3A1-AF98-4729-BC73-517A775D3AE3

Q35054462-80C10918-9AB7-4353-8898-2A90928E00BA

Q35054462-8D4D8E41-71CA-428B-AABA-13703C298AEF

Q35054462-962AD6B1-E2E8-41A2-8281-1A9E9225D3C4

P304

Q35054462-7C951F1D-B03A-4BDE-B9BF-DCE8785CAC11

P31

Q35054462-E364414E-117E-486F-9DC7-D77C35348FBC

P356

Q35054462-79F640CA-5EAC-48A9-8212-4E2D8218EFA5

P433

Q35054462-89BD5898-BFB3-4CA7-A805-9032666B1E0F

P478

Q35054462-CF743F59-B4D0-465C-851B-E047740DB465

P50

Q35054462-8CA62DFA-13A7-4FE6-B749-7F003806744B

Q35054462-B38BEF85-EBE4-410B-A07D-CDF5AFA44176

P577

Q35054462-FE7B28AB-642F-44BF-BFE5-CB9F015B99C6

P698

Q35054462-9EB02B5E-5D16-4D5F-8A7A-90C7D8FF5B26

P921

Q35054462-261352F8-5C22-4FDC-AD24-6159F4E26657

P932

Q35054462-44246AA4-91DC-4994-8665-BBB69CCA9458

P356

SAJHIVMED.V12I1.214

P1433

Southern African journal of HIV medicine

P1476

THE RISKS OF CONCURRENT TREATM ...... TH HIV-ASSOCIATED TUBERCULOSIS

@en

P2093

Nicci Wearne

http://www.w3.org/2001/XMLSchema#string

Rosie Burton

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity.

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Tenofovir-induced kidney injury.

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

P304

43-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4102/SAJHIVMED.V12I1.214

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Graeme Meintjes

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21695064

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3118283

http://www.w3.org/2001/XMLSchema#string